NasdaqGM - Nasdaq Real Time Price USD

Maze Therapeutics, Inc. (MAZE)

Compare

8.41

+0.23

+(2.81%)

At close: April 17 at 4:00:01 PM EDT

8.41

0.00

(0.00%)

After hours: April 17 at 4:01:59 PM EDT

US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps

As the U.S. market grapples with volatility, marked by mixed performances in major indices and concerns over tariffs impacting economic growth, small-cap stocks have become a focal point for investors seeking potential opportunities beyond the turbulence affecting large caps. In this climate, identifying promising small-cap companies like ZJK Industrial involves looking for those with strong fundamentals and resilience to external pressures, making them potential undiscovered gems amid...

Simply Wall St. 8 hours ago

MAZE
+2.81%
SWBI

ZJK
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicin

GlobeNewswire 17 days ago

MAZE
+2.81%
Maze Therapeutics receives positive ratings following recent IPO

Investing.com -- Maze Therapeutics Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.

Investing.com last month

MAZE
+2.81%
Maze Therapeutics doses first subject in Phase II AKD treatment trial

The proof-of-concept interim data is expected in the first quarter of 2026.

Clinical Trials Arena 2 months ago

MAZE
+2.81%
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD). MZE829 is an oral, small m

GlobeNewswire 2 months ago

MAZE
+2.81%
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds from the

GlobeNewswire 2 months ago

MAZE
+2.81%
Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

BioPharma Dive 2 months ago

MTSR
+11.51%
MAZE
+2.81%

Performance Overview

Return	MAZE	S&P 500 (^GSPC)
YTD	-47.83%	-10.18%
1-Year	-47.83%	+5.19%
3-Year	-47.83%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Maze Therapeutics, Inc. (MAZE)

US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics receives positive ratings following recent IPO

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Metsera, Maze secure combined $415 million in IPOs

Performance Overview